CME in Minutes: Education in Primary Care

Please visit answersincme.com/860/101834101-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Simpa S. Salami, MD, MPH; and Neal D. Shore, MD, FACS. In this activity, experts in prostate cancer discuss new evidence for individualized, evidence-based treatment strategies in metastatic hormone-sensitive disease. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the most recent data informing the standard of care treatment options for mHSPC; Integrate patient-, disease-, and therapy-related factors to develop individualized, evidence-based treatment strategies for mHSPC; and Design patient-centered care approaches...

Please visit answersincme.com/ZPW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by David R. Staskin, MD. In this activity, an expert in urology discusses strategies to diagnose and individualize treatment for overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH), including the role of beta-3 adrenergic agonists and guideline-based care. Upon completion of this activity, participants should be better able to: Identify strategies to diagnose overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH); Assess the evidence for beta-3 adrenergic agonists in the treatment of OAB among patients...

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong...

Please visit answersincme.com/KJW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aman Chauhan, MD and Rhonda K. Yantiss, MD. In this activity, experts in medical oncology and pathology discuss identification and treatment of extrapulmonary neuroendocrine carcinomas and extrapulmonary neuroendocrine tumors. Upon completion of this activity, participants should be better able to: Differentiate extrapulmonary neuroendocrine carcinoma (EP-NEC) from extrapulmonary neuroendocrine tumors (EP-NETs); Identify diagnostic and pathological approaches to improve the recognition and accurate classification of EP-NEC and EP-NET; Evaluate emerging clinical data on DLL3-targeting bispecific TCE agents in the...

Please visit answersincme.com/BJN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Rajesh Gandhi, MD. In this activity, an expert in infectious diseases discusses novel oral antiretroviral therapy (ART) for the management of human immunodeficiency virus (HIV). Upon completion of this activity, participants should be better able to: Recognize the rationale for novel oral ART regimens in the management of virologically suppressed HIV infection; Review the clinical impact of novel emerging oral ART regimens for patients with virologically suppressed HIV infection; and Formulate patient-centered strategies for optimizing the personalized management...

Please visit answersincme.com/DDT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Robert Haddad, MD. In this activity, an expert in medical oncology discusses locally advanced head and neck squamous cell carcinoma (LA HNSCC). Upon completion of this activity, participants should be better able to: Discuss the clinical implications of the latest data for approved and recommended regimens for resectable LA HNSCC in the pre- and postoperative settings; Outline strategies to integrate immunotherapy into pre- and postoperative settings for resectable LA HNSCC, in the context of conventional treatment; and Apply...

Please visit answersincme.com/860/103093269-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephanie Faubion, MD, MBA, FACP, MSCP and Shelby Harris, PsyD, CBSM, DBSM. In this activity, experts in menopause discuss diagnosis and management of sleep disturbances due to vasomotor symptoms. Upon completion of this activity, participants should be better able to: Recognize the burden of menopause-related VMS occurring during sleep; Explain the clinical significance of the latest data for novel non-hormonal pharmacotherapies in the treatment of menopause-related VMS, including those occurring during sleep; Identify patients with menopause-related VMS and...

Please visit answersincme.com/RAH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alan G. Kaplan, MD, CCFP(EM), FCFP, CPC(HC); Sherilyn Houle, BSP, PhD, CTH, AFTM RCPS(Glasg), FISTM; and Aakash Modi, MD, CFPC, ABFM, FAAFP. In this activity, two experts in adult pneumococcal disease immunization discuss strategies to close the prevention gap in primary care and pharmacy practice. Upon completion of this activity, participants should be better able to: Describe the burden of adult pneumococcal disease in Canada, including the role of the aging immune system; Recognize opportunities...

Please visit answersincme.com/TNH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nick H. Kim, MD and Vallerie V. McLaughlin, MD. In this activity, experts in cardiovascular medicine and pulmonology discuss pulmonary arterial hypertension (PAH). Upon completion of this activity, participants should be better able to: Recognize the importance of treatment escalation for appropriate patients with PAH; Design risk-based treatment escalation plans for patients with PAH; Review the clinical impact of guideline-recommended therapies for risk-based treatment escalation in PAH; and Propose practical considerations to enhance outcomes for patients with PAH...

Please visit answersincme.com/FAJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nancy L. Kuntz, MD; Vanessa Battista, DNP, MBA, CPNP-PC, CHPPN, FPCN, FAAN; and Ethan Hilgert. In this activity, experts in the management of spinal muscular atrophy (SMA) discuss the diagnosis and treatment of late-onset SMA (type 3b, 4) in adults. Upon completion of this activity, participants should be better able to: Recognize clinical features that are suggestive of SMA in adults; Review the evidence for approved disease-modifying therapies in adult patients with SMA; and Apply strategies that address barriers...

Please visit answersincme.com/GXT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sarah Donahue, MPH, ANP, AOCNP. In this activity an expert in breast cancer discusses the efficacy and safety of oral SERDs in HR+, HER2- advanced breast cancer. Upon completion of this activity, participants should be better able to: Review the evidence-based use of oral SERDs in the treatment plan for patients with HR+, HER2- advanced breast cancer; Specify the key roles of nurses and NPs in optimizing the overall care for patients with HR+, HER2...

Please visit answersincme.com/860/240201346-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Shannon Salvador, MD, MSc, FRCSC; Sheila Wijayasinghe, MD, CCFP, MSCP; and Christine Palmay, HBArtSci, MD, CCFP. In this activity, experts in HPV vaccination discuss its critical role in cancer prevention, the latest guideline updates, and strategies to improve uptake in populations of interest. Upon completion of this activity, participants should be better able to: Describe the prevalence and impact of human papilloma virus (HPV) infection and its associated cancers across diverse patient populations; Explain the rationale for HPV...

Please visit answersincme.com/MRQ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alexandra K. Golant, MD; Peter Lio, MD, FAAD; and Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP. In this activity, experts in dermatology discuss the OX40L pathway and its potential role in the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Identify the rationale for targeting the OX40/OX40 ligand (OX40L) pathway in the treatment of moderate-to-severe atopic dermatitis (AD); Assess the evidence on efficacy outcomes and safety profiles of...

Please visit answersincme.com/UMW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey Neul, MD, PhD. n this activity, an expert in pediatrics and neurology discusses the latest data for treatment of Rett syndrome. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for investigational neuroactive pharmacologic therapies in the treatment of RTT; and Translate the latest data into treatment considerations for approved and emerging therapies in RTT.

Please visit answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Stephen V. Liu, MD and Amber Fake. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC; Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC; Evaluate the clinical evidence of...

Please visit answersincme.com/860/IME_2025_00012595-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John V. Heymach, MD, PhD; and Mark Awad, MD, PhD. In this activity, experts in oncology discuss the role of dual and HER2-selective oral tyrosine kinase inhibitors in patients with HER2-mutated non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Specify how TKIs may address unmet therapeutic needs for diverse patient populations with HER2-mutated NSCLC; Interpret the clinical evidence for approved oral TKIs for patients with HER2-mutated NS...

Please visit answersincme.com/860/240201372-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jeffrey Habert, MD, CCFP, FCFP and Maria Anton, RPh, BSc, PharmD. In this activity, experts in type 2 diabetes discuss guideline-recommended goals of treatment and strategies to develop personalized plans that incorporate the latest GLP-1–based therapies. Upon completion of this activity, participants should be better able to: Propose guideline-recommended goals of treatment for adults with T2D; Formulate personalized, evidence-based treatment plans for T2D; and Apply practical strategies for the initiation and integration of contemporary therapies for ad...

Please visit answersincme.com/860/101385133-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Peter A. Fasching, MD; Michael Gnant, MD, FACS; and Cristina Saura Manich, MD, PhD. In this activity, experts in breast cancer discuss new evidence in neoadjuvant and adjuvant care of early disease. Upon completion of this activity, participants should be better able to: Describe multidisciplinary viewpoints on the role that HER2-directed ADCs may play in the (neo)adjuvant setting for HER2-positive early-stage breast cancer; Evaluate evidence for the (neo)adjuvant use of HER2-directed ADCs in...

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.

Please visit answersincme.com/YVT860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michael Mak, MD, FRCPC, DRCPSC, FCPA, FAPA, FAASM; and Sabrina Kwon, BSc, MD. In this activity, experts in sleep and primary care discuss strategies for the screening, diagnosis, and treatment of adults with obesity and obstructive sleep apnea. Upon completion of this activity, participants should be better able to: Recognize key clinical and diagnostic challenges in identifying obstructive sleep apnea (OSA) in adults with obesity; Evaluate the role of weight management strategies, including incretin-based therapies, in the comprehensive...

Please visit answersincme.com/860/102771731-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sairah Ahmed, MD; and Sharon Marie Castellino, MD, MSc. In this activity, experts in Hodgkin lymphoma discuss unmet needs and emerging data in the treatment of classical HL. Upon completion of this activity, participants should be better able to: Explain the rationale for investigating ICI-based regimens for previously untreated advanced cHL; Interpret the emerging clinical evidence for ICI-based regimens in patients with previously untreated advanced cHL; and Propose how emerging ICI-based regimens, as they become available, may fit...

Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–target...

Please visit answersincme.com/NYR860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Liss, MD, MSCP; Denise Black, MD, FRCSC; and Danielle Covarrubias. In this activity, experts in women’s health, joined by a patient advocate, discuss the burden of menopause-related vasomotor symptoms (VMS) and novel management strategies. Upon completion of this activity, participants should be better able to: Identify the impact and burden of VMS as a consequence of menopause; Outline the clinical rationale for novel therapeutic approaches to manage menopause-related VMS; Evaluate the efficacy and safety of novel ne...

Please visit answersincme.com/KAF860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jill Trinacty, MD, FRCPC, ABOM. In this activity, an expert in endocrinology discusses incretin-based therapies for the management of cardiometabolic risk. Upon completion of this activity, participants should be better able to: Describe the role of incretin-based therapies in cardiovascular risk reduction; Compare cardiovascular outcomes evidence across incretin-based therapies to inform clinical discussions; and Recognize opportunities to identify and address cardiometabolic risk in a multidisciplinary team setting.

Please visit answersincme.com/860/102701687-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Mike Sharma, MD, MSc; and Richard A. Bernstein, MD, PhD. In this activity, experts in stroke discuss post-stroke care and long-term secondary stroke prevention. Upon completion of this activity, participants should be better able to: Discuss evidence-based strategies for secondary stroke prevention, including risk factor modification; Outline the potential role of FXIa inhibitors in closing current long-term management gaps for patients who have had a non-cardioembolic ischemic stroke or TIA; and Design multidisciplinary, long-term secondary stroke treatment plans...

Please visit answersincme.com/FNW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Karen P. Acker, MD. In this activity, an expert in microbiology and immunology discusses recommendations and strategies for enhancing the uptake of respiratory syncytial virus (RSV) immunization in infants. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) immunization in infants and children; Review guideline-recommended immunization strategies for RSV prevention in infants, including the benefits and limitations of maternal versus infant immunization approaches; and Formulate effective, patient-centered communication...

Please visit answersincme.com/860/101064703-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Muthiah Vaduganathan, MD, MPH and Nosheen Reza, MD, MS. In this activity, experts in cardio-kidney-metabolic syndrome (CKM) discuss emerging evidence on nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) and practical strategies for incorporating these therapies into care for patients with heart failure, with or without chronic kidney disease (CKD) or type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Specify the rationale for nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) as treatment for adult patients with...

Please visit answersincme.com/860/102620367-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Keith C. Ferdinand, MD; and Henry J. Michtalik, MD, MPH, MHS. IIn this activity, experts in preventive cardiology and hospital medicine discuss secondary stroke prevention strategies for hospitalists and internists. Upon completion of this activity, participants should be better able to: Evaluate guideline-recommended secondary stroke prevention strategies after ischemic stroke or TIA; Describe the clinical rationale for FXIa inhibitors; Discuss the clinical significance of the latest efficacy and safety data for FXIa inhibitors in secondary stroke prevention; and...

Please visit answersincme.com/QSK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Markus Cornberg, MD. In this activity, an expert in infectious diseases discusses the management of patients with hepatitis C virus (HCV) infection. Upon completion of this activity, participants should be better able to: Discuss the factors influencing timely intervention in hepatitis C virus (HCV) management; Describe recommended HCV screening strategies to increase uptake in underserved populations; and Recognize appropriate criteria for initiating simplified HCV therapy or referring patients for specialist care.

Please visit answersincme.com/FGV860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Janet B. McGill, MD, MA, FACP, MACE. In this activity, an expert in the management of diabetes discusses evolving data on emerging strategies to enhance cardiorenal outcomes in patients with type 1 diabetes (T1D). Upon completion of this activity, participants should be better able to: Review the limitations of current treatment strategies for chronic kidney disease (CKD) in type 1 diabetes (T1D); Identify the pathophysiologic mechanisms underlying CKD in patients with T1D; and Assess current and emerging...

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Please visit answersincme.com/AGN860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Ferhina Ali, MD, MPH, FASRS. In this activity, an expert in retinal diseases discusses anti-VEGF treatment of diabetic macular edema. Upon completion of this activity, participants should be better able to: Recognize factors that contribute to patients' treatment burden with intravitreal anti–vascular endothelial growth factor (VEGF) therapies for diabetic macular edema (DME); Assess the clinical profiles of long-acting intravitreal anti-VEGF agents for DME; and Recommend individualized strategies to enhance long-term treatment outcomes for patients with DME.

Please visit answersincme.com/KWA860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Benjamin Levy, MD, FASCO. In this activity, an expert in oncology discusses the use of subcutaneous immune checkpoint inhibitors. Upon completion of this activity, participants should be better able to: Describe the rationale for subcutaneous (SC) immune checkpoint inhibitor (ICI) administration in the context of standard care with intravenous (IV) formulations in patients with advanced solid tumors; Review the evidence for SC formulations of ICIs compared with IV formulations in patients with advanced solid tumors; and Propose patient-centered...

Please visit answersincme.com/SST860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jennifer Vittorio, MD, FAASLD. In this activity, an expert in hepatology discusses the treatment of cholestatic pruritus. Upon completion of this activity, participants should be better able to: Explain the rationale for new treatment strategies for the management of cholestatic pruritus; Evaluate clinical trial data and safety profiles of new and emerging ileal bile acid transporter (IBAT) inhibitors; and Implement best practices for patient selection and initiation of IBAT inhibitor therapy.

Please visit answersincme.com/HAC860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Kohei Shitara, MD, PhD. In this activity, an expert in gastrointestinal oncology discusses the latest data for the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma. Upon completion of this activity, participants should be better able to: Discuss the latest efficacy and safety data for HER2-directed antibody-drug conjugates in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma; and Translate the latest data for the treatment of gastric and GEJ adenocarcinoma within the context of the current...

Please visit answersincme.com/860/240201375-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by James Michael Ramsahai, BSc, MD, PhD, FRCPC and Nan Zhao, BSc, MD, FRCPC. In this activity, experts in managing severe eosinophilic asthma discuss evidence-based strategies for personalizing biologic therapy, reducing steroid burden, and optimizing treatment in the setting of overlapping eosinophilic diseases. Upon completion of this activity, participants should be better able to: Identify strategies to individualize the selection of biologic therapies for patients with severe eosinophilic asthma based on the latest clinical and real-world evidence; Evaluate the...

Please visit answersincme.com/DZU860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Michelle Jacobson, MD, MHSc, FRCSC, MSCP; Nadia Harbeck, MD, PhD; and Renate Haidinger. In this activity, experts in breast cancer and menopause discuss the burden of vasomotor symptoms (VMS) due to breast cancer treatment and the emerging role of neurokinin (NK) receptor antagonists in alleviating these symptoms in practice, with insights from a patient advocate. Upon completion of this activity, participants should be better able to: Recognize VMS as a consequence of breast cancer treatment; Outline the clinical...

Please visit answersincme.com/860/MED-CMB-03166-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Samuel S. Gidding, MD; Pamela B. Morris, MD, FACC and Allison Jamison. In this activity, experts in homozygous familial hypercholesterolemia (HoFH) discuss screening, diagnosis, and treatment strategies to support effective management of this rare inherited lipid disorder. Upon completion of this activity, participants should be better able to: Identify strategies to screen and diagnose HoFH; Review the treatment landscape of HoFH, including the role of LDLR-independent therapies; and Outline patient-centered practical strategies to enhance the management of...

Please visit answersincme.com/860/240201356-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sue D. Pedersen, MD, FRCPC, DABOM; Leon Waye, MD; and Basel Bari, MD, MCFP. In this activity, experts in obesity discuss treatment management with a focus on the role of incretin-based therapies. Upon completion of this activity, participants should be better able to: Explain the rationale for managing obesity as a chronic, treatable disease; Discuss the latest evidence for incretin-based therapies in the management of obesity, including clinical outcomes and safety profiles; and Identify patients who might benefit...

Please visit answersincme.com/CZS860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Giuseppe Curigliano, MD, PhD. In this activity, an expert in oncology discusses the differentiation of patients with HER2-low/ultralow/negative advanced breast cancer and treatment with antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Differentiate HER2-low, -ultralow, and -negative advanced breast cancer; Identify patients with HER2-low and -ultralow advanced breast cancer who would benefit from treatment with antibody-drug conjugates; and Apply evidence-based strategies to connect testing to treatment in patients...